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We investigated G protein-stimulated release of ATP from human umbilical vein endothelial cells (HUVECs) using the G protein
stimulant compound 48/80. Application of compound 48/80 resulted in dose-dependent ATP evolution from cultured HUVECs. This release
was not cytotoxic as demonstrated by a lactate dehydrogenase assay and the ability of the cells to load and retain the viability dye calcein
following stimulation. Mastoparan also stimulated release of ATP, further suggesting the process was G-protein initiated. This G protein was
insensitive to pertussis toxin and appeared to be of the Gq-subtype. The ATP efflux was completely abolished in the presence of EGTA and
thapsigargin signifying a strict Ca2+ dependence. Furthermore, compound 48/80-induced release was significantly decreased in cells
pretreated with the phospholipase C inhibitor U73122. Thus, the release pathway appears to proceed through an increase in intracellular Ca2+
via PLC activation. Additionally, the G protein-initiated release was attenuated by pretreatment of the cells with either phorbol ester or
indolactam V, both activators of protein kinase C. Finally, ATP release was not affected by treating HUVECs with nitric oxide synthase
(NOS) inhibitors or glybenclamide.
D 2004 Elsevier B.V. All rights reserved.
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The role of ATP as an intercellular messenger has
attracted widespread interest over the past 10 years. The
binding of ATP to purinergic receptors on the surface of
cells initiates receptor-mediated responses. These purinergic
receptors are classified into two categories: ion channel-
coupled P2X type and G protein-coupled P2Y type. P2
receptors are further classified by their pharmacological and
genetic properties [1,2]. Their activation initiates several
different second messenger pathways in many types of cells,
including neurons, smooth muscle cells, mast cells, and
epithelial cells [3]. The most thoroughly investigated of
these pathways is the elevation of intracellular Ca2+ levels0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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[1,4,5] triphosphate (IP3). IP3 binds to receptors on the
endoplasmic reticulum releasing stored Ca2+. Increasing
intracellular Ca2+ initiates/regulates numerous cellular
responses, such as insulin secretion in h-cells [4], synaptic
transmission in neurons [5,6], mast cell degranulation [7],
and platelet aggregation at injury sites [8].
ATP signaling in endothelial cells appears to be
important for proper endothelium function. Activation of
endothelial cells by ATP in vitro has been shown to
increase cytosolic Ca2+ levels and consequently to cause
production of nitric oxide (NO) [9]. NO regulates
endothelium vascular tone, inhibits platelet aggregation,
and reduces vascular smooth muscle proliferation in the
cardiovascular system [10]. Ca2+ signaling also activates
secretion of von Willebrand factor from the Wiebel-Palade
bodies, the main exocytotic vesicle in endothelial cells
[11]. A number of other important effects occur inta 1693 (2004) 135–146
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including release of prostacyclin and endothelin-1, and an
enhancement in microvascular permeability (see Ref. [12]
for a review).
While much is known about the stimulatory effects of
ATP on endothelial cells, the source of this ATP is unclear.
One possibility is secretion of ATP stored in exocytotic
vesicles. A number of researchers have reported ATP being
copackaged with either norepinephrine or acetylcholine in
neuronal synaptic vesicles where it acts as a fast excitatory
neurotransmitter [13–15]. Shear stress has been reported to
induce release of ATP in endothelial cells via exocytosis
[35]. The cytoplasm is the other obvious source for
release. Under extreme circumstances, ATP may be
liberated from a cell’s cytoplasm following lysis. However,
recent evidence suggests that release of ATP from the
cytosolic pool may also occur in a regulated, non-cytotoxic
manner. ATP is reported to be released from many cell
types via ATP binding cassette proteins, such as the cystic
fibrosis transmembrane conductance regulator (CFTR)
chloride channel [16]. The concept of this ion channel
being able to pass a large highly charged molecule like
ATP is at this time highly controversial, and numerous
researchers have reported conflicting results on the matter
[15,17].
Mechanical stimulation also results in release of ATP in
numerous cell lines [18–20]. Stout et al. [21] have recently
postulated that ATP is released through connexin proteins in
mechanically stimulated astrocytes. Connexins commonly
form gap junctions between cells, but can also form
channels to the extracellular matrix termed hemichannels
[22]. The presence of hemichannels and their ability to
release small dye molecules has been known for some time.
Cotrina et al. [19] previously discovered that C6 glioma
cells with increased connexin43 expression release larger
amounts of ATP than do control cells. A recent report by
Arcuino et al. [23] lends support to this proposed release
mechanism. They note that release of ATP from the
cytoplasmic pool represents a viable method for cellular
communication in nonexcitable cells. Furthermore, numer-
ous surrounding cells can be influenced by the release of
ATP in this manner, because the concentration of ATP in the
cytoplasm is ~2 mM [23].
In this study, we performed experiments on human
umbilical vein endothelial cells (HUVECs), a popular model
for the investigation of endothelium function. The G protein
agonist compound 48/80 was employed to stimulate release
of ATP from HUVECs. Chemiluminescence produced by
the reaction of luciferin and ATP in the presence of
luciferase was monitored in real time on a microscope
equipped with an intensified CCD camera. Ca2+ imaging
was conducted on the same setup and served in both
experimental and control capacities. Several of the key
enzymes and second messengers involved in this ATP
release mechanism were identified, and release in HUVECs
was compared to other proposed pathways.2. Experimental procedures
2.1. Chemicals
Compound 48/80, thapsigargin, and EGTA were pur-
chased from Sigma (St. Louis, MO). Firefly luciferase (from
Photinus pyralis) and d-luciferin were obtained from both
Sigma and R&D Systems (Minneapolis, MN). BAPTAAM,
Fluo-3 AM, calcein AM, and Pluronic F-127 were from
Molecular Probes (Eugene, OR). U73122 (1-[6-([(17h)-3-
methoxyestra-1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyr-
role-2,5-dione) and U73343 (1-[6-([(17h)-3-methoxyestra-
1,3,5(10)-trien-17-yl]amino)hexyl]-2,5-pyrrolidinedione)
were purchased from both Calbiochem (La Jolla, CA) and
Sigma. All other drugs were from Calbiochem. U73122,
U73343, phorbol-12-mystirate-13-acetate (PMA), Go6893,
bisindolylmaleimide (BIM), indolactam V, thapsigargin,
BAPTA AM, Fluo-3 AM, and calcein AM were dissolved
in dimethylsulfoxide (DMSO, Sigma) as stock solutions.
BAPTAAM, Fluo-3 AM, and calcein AMwere diluted 1000-
fold in buffer containing 0.1% Pluronic F-127 (20% in
DMSO) to aid in solubilization of the dye. All other drugs
were diluted to the pretreatment concentration in imaging
buffer. The concentration of DMSO in pretreatment solutions
never exceeded 0.3%. In control experiments, all drug
compounds were tested for and displayed no interference
with the ATP-luciferin-luciferase bioluminescent reaction.
Other drug compounds, such as suramin, reactive blue 2 and
gadolinium ion, interfered with bioluminescent imaging and
thus were not employed in this study. For the specific case of
compound 48/80, injection of 20 nM ATP yielded 98.9% of
the chemiluminescence signal for luciferase containing 1 mg/
ml compound 48/80 as luciferase solution alone.
2.2. Cell Cultures
HUVECs were purchased from American Type Culture
Collection (Manassas, VA). These cells were in passage 14
when ordered. Experiments were performed only on
cultures between 15 and 25 total passages to ensure minimal
chance of change in cellular phenotype. Cells were grown in
Medium 199 (Life Technologies, Rockville, MD) supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 Ag/ml streptomycin. Cells were plated on 2222-
mm square coverslips coated with poly-l-lysine (Sigma)
substrate. Teflon O-rings (Small Parts, Inc., Logansport, IN)
were attached to coverslips with Sylgard 184 (Dow
Corning, Midland, MI) prior to coating with poly-l-lysine
and acted as solution chambers. Cells were grown at 37 8C
in an atmosphere of 95% air–5% CO2. Prior to stimulation,
cells were rinsed with buffer (135 mM NaCl, 5 mM KCl, 2
mM MgCl2, 2 mM CaCl2, 10 mM HEPES (4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid) and 10 mM glu-
cose (pH=7.3)). In experiments performed with buffers
containing different concentrations of Ca2+, the ionic
strength of the solution was maintained by varying the
Table 1
Cytotoxicity tests for compound 48/80 on HUVECs
(A)
Stimulant LDH release
Buffer 0.62F0.11
Compound 48/80 1.15F0.13
A23187 0.97F0.51
Digitonin 100F6.16
(B)
Stimulant Number of cells loading calcein
Buffer 129.2F5.1
Compound 48/80 136.0F5.2
(C)
Stimulant % of cells leaking calcein
Buffer 1.7F1.7
Compound 48/80 48.9F9.8
(A) Quantities of LDH released from HUVECs stimulated with buffer
(N=5), 25 Ag/ml compound 48/80 (N=7), 5 AM A23187 (N=7), or 40 AM
digitonin (N=7). (B) Number of cells able to load and maintain calcein AM
after stimulation with buffer (N=13) or 16.8 Ag/ml compound 48/80
(N=19). (C) Percent of calcein-loaded HUVECs that lost fluorescence
30 min after addition of either buffer (N=3) or 15 Ag/ml compound 48/80
(N=6).
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ducted only on confluent cultures.
2.3. ATP Imaging
ATP imaging was performed on the stage of an inverted
microscope (Axiovert 100 TV, Zeiss, Germany). Chemilu-
minescence signal was collected with a Zeiss Apochromat
20 microscope objective (NA=0.75) and detected with an
intensified charge-coupled device (iCCD; EEV 576384
pixels CCD chip, Roper Scientific, Trenton, NJ) attached to
the camera mount of the microscope. Cells were incubated
in 100-Al buffer containing 100 Ag/ml firefly luciferase and
205 AM d-luciferin. Images were collected at a frequency of
1.33 Hz with 500-ms exposure times. All experiments were
performed at room temperature. Stimulant was applied to
the cells via a 10-Al Hamilton syringe within the first 10
frames of the collected images. The camera offset was
removed by subtracting an image file collected with the
camera shutter closed.
2.4. Ca2+ imaging
The same experimental setup was utilized for Ca2+
imaging as was used for ATP imaging. HUVECs were
loaded for 50 min at room temperature with 8.85 AM Fluo-3
AM in buffer with reduced Ca2+ (200 AM). The cells were
then incubated, also at room temperature, for an additional
30 min in buffer to allow for complete de-esterification of
the Fluo-3. Excitation was accomplished using a Zeiss Atto
Arc HBO 100-W mercury lamp with a 475F20-nm
bandpass filter. Fluorescence emission was collected
through a 505-nm dichroic mirror and isolated with a
530F18-nm bandpass filter. No autofluorescence was
detected at the wavelengths utilized. The exposure time of
the iCCD and the power of the mercury lamp were varied
based on the efficiency of the Fluo-3 loading of each
individual coverslip.
2.5. Cytotoxicity assay
LDH assays (Sigma) were performed at room temper-
ature on a UV–VIS spectrometer (HP 8452A Diode Array
Spectrophotometer, Hewlett Packard, Palo Alto, CA).
Coverslips were rinsed with buffer three times at 15-min
intervals. The final rinse from each coverslip was collected
as a background sample. Compound 48/80, A23187, or
buffer was added to each coverslip and then sampled after
10 min. The LDH content was determined by adding the
assay solution (50 Al) to each sample (100 Al) and allowing
the assay reaction to proceed for 25 min. The reaction was
halted with 1 N HCl (15 Al), and the peak absorbance of
each sample was evaluated from 480 to 500 nm to quantitate
LDH. For control coverslips (buffer as stimulant), an
additional step was performed. After the background and
experimental samples were obtained, 20 AM digitonin wasadded to the coverslip to achieve total lysis of the cells.
Complete cell lysis was estimated by optically observing the
morphological change of digitonin-stimulated cells. The
digitonin-treated sample was diluted with buffer until its
absorbance neared that of the compound 48/80 and A23187-
treated samples. This sample was assayed identically to the
others and marked the maximum releasable LDH.
2.6. Calcein loading efficiency
Calcein loading efficiency was assessed on the same
fluorescence microscope setup as was used for Ca2+
imaging. Dishes containing HUVECs were stimulated with
compound 48/80 or control (buffer). After 15 min, the cells
were rinsed and incubated in buffer containing 1 AM calcein
AM for 45 min at room temperature and in buffer for 20 min
at room temperature to allow for loading and complete de-
esterification of calcein, respectively. Cell viability was
expressed as the percent of cells able to load calcein.
2.7. Calcein leakage
Again the same instrumental setup was employed for
calcein leakage experiments as was for Ca2+ imaging.
Dishes of HUVECs were loaded with 1 AM calcein AM in
buffer for 45 min at room temperature. After incubation in
buffer for 20 min to allow de-esterification of the dye,
compound 48/80 or buffer was added to the dishes. The
number of cells exhibiting fluorescence was monitored prior
to and following stimulation. The percent of calcein-loaded
Fig. 1. Compound 48/80-induced release of ATP in HUVECs. ATP signal was monitored from cultured HUVECs stimulated with 15 Ag/ml compound
48/80. (A) Single frames of data are shown at various times after stimulation. (B) Concentration of ATP efflux following stimulation is plotted versus
time after stimulation. (C) The dose dependence of ATP release is depicted in a plot of the maximum ATP release versus compound 48/80 concentration.
The overall curve is the combined data from five separate dose response curves obtained from HUVECs in different passages. All data points represent
the combined data from at least five independent compound 48/80 injections, except for [compound 48/80]=0 and 5 Ag/ml, for which only three
injections were performed.
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compound 48/80 and buffer-stimulated dishes.
2.8. Data presentation/analysis
Chemiluminescence and fluorescence signal were
obtained and processed with Winview32 software (Roper
Scientific). The mean chemiluminescence signal was
calculated for each frame of data. The net ATP signal was
calculated by subtracting the pre-stimulation average signal
from the maximum ATP signal. Concentrations of ATP
release were calculated from a calibration curve obtained
from imaging solution and ATP standards. Other ATP data
are reported as a percentage (of counts) of the experimental
versus the control experiments (compound 48/80 stimula-
tion of untreated dishes, unless otherwise noted). For
temporal responses, the initiation and maximal times
represent the 10% and 90% maximal signals, respectively.
Calcium fluorescence images were analyzed by subtracting
a prestimulation image from all poststimulation images. A
cell was deemed as having signal only if its fluorescence
after stimulation was at least 10 times the background
standard deviation. Identical processing was performed for
calcein images except that the poststimulation image was
subtracted from a prestimulation image for calcein leakage
experiments. Standard errors were determined for each
condition based on the number of samples analyzed. A P
value of b0.05 was considered significant as calculated by
the Student’s t-test for paired experiments.Fig. 2. G protein dependence of compound 48/80-induced release of ATP
from HUVECs. HUVECs were stimulated with 10 AM mastoparan.
HUVECs pretreated overnight with 250 ng/ml PTX or buffer were
stimulated with 15 Ag/ml compound 48/80. Representative time courses
of ATP release are shown.3. Results
The toxicity of compound 48/80 to the HUVECs was
first investigated. For this purpose, an LDH assay was
employed. LDH is a large cytoplasmic protein whose
release is a marker of the loss of cell membrane integrity.
HUVEC plates were sampled prior to and following
activation with compound 48/80, buffer, or the Ca2+
ionophore A23187. A23187 was utilized as a control
stimulant since it activates HUVECs by increasing the
cell’s intracellular Ca2+ concentration, as does compound
48/80 (see below). Buffer-stimulated control plates were
sampled further after lysing the cells with digitonin. The
results of the LDH assay are depicted in Table 1A.
Compound 48/80-induced release of LDH was almost two
orders of magnitude lower than that obtained from cell lysis.
Furthermore, the LDH levels obtained for compound 48/80
stimulation were not significantly different from those
obtained for stimulation with A23187 or buffer. The
possible cytotoxic effects of compound 48/80 were further
examined with the cell viability dye calcein AM. HUVECs
were able to load and maintain calcein dye both prior to and
after exposure of HUVECs to 15 Ag/ml compound 48/80
(Table 1B). A second test for cytotoxicity using calcein is
the ability of a cell to maintain the loaded dye uponstimulation. When 15 Ag/ml compound 48/80 was added to
calcein-loaded HUVECs, 48.9F9.8% of the cells failed to
maintain calcein fluorescence (Table 1C). Taken together,
the three assays suggest that upon stimulation with
compound 48/80 the HUVEC membrane is permeable to
calcein (622 Da) but not LDH (134 kDa). This permeability
to calcein is not permanent and ceases upon removal of
compound 48/80.
Addition of the G protein stimulant compound 48/80 to
confluent coverslips of HUVECs caused release of cellular
ATP, as depicted in Fig. 1 (A and B). ATP release was
initiated 41.1F1.8 s (N=30) after addition of 15 Ag/ml
compound 48/80. The ATP signal reached a maximum at
126.2F5.8 s and slowly decreased back to basal levels (10–
15 min). For the injection displayed in Fig. 1 (A and B),
basal release of ATP was below our detection limits (b 5
nM) while the maximal release was at approximately 600
nM ATP. Since a perfusion system was not utilized in these
experiments, the slow decrease to basal levels could be a
result of the continued presence of compound 48/80 and/or
from ATP-induced ATP release from HUVECs. The dose
dependence of compound 48/80-stimulated release of ATP
is shown in Fig. 1C. ATP efflux was not detected at
compound 48/80 concentrations lower than 5 Ag/ml and
plateaued at ~60 Ag/ml compound 48/80 at around 4 AM
ATP.
Next we attempted to confirm that a G protein was
indeed the initiation site for compound 48/80-induced ATP
release. Direct stimulation of HUVECs with another G
protein stimulant, mastoparan, also produced significant
release of ATP. As shown in Fig. 2, mastoparan induced as
much ATP release as did compound 48/80 (67.2F10.8%
(N=3)). The kinetics of ATP release (38.4F5.8 s and
104.1F8.1 s, N=4) was also similar to that of compound 48/
80-induced release. PTX, an inhibitor of Gi and Go but not
Fig. 3. Compound 48/80-induced increases in intracellular Ca2+ and Ca2+-dependent release of ATP from HUVECs. Intracellular stores of Ca2+ were depleted
by incubation of HUVECs with 250 nM thapsigargin for 20 min, and extracellular Ca2+ was removed by bathing cells in buffer with Ca2+ removed and 100 AM
EGTA added to remove any residual Ca2+ ions (Tg/EGTA). Compound 48/80 induced intracellular Ca2+ increases in HUVECs loaded with Fluo-3. Single
frames of Ca2+ imaging data are depicted at various times after stimulation with 15 Ag/ml compound 48/80 (A). Representative time courses of ATP release (B)
and Ca2+ signaling (C) are depicted for HUVECs stimulated with 15 Ag/ml compound 48/80 (Tg/EGTA and 48/80), 10 AM Ca2+ ionophore (A23187), 5 AM
thapsigargin (Tg) or buffer. Inset for B: Zoomed-in look at the lack of ATP release caused by thapsigargin, A23187, and buffer.
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ment of G proteins in initiating release of ATP. As shown in
Fig. 2, overnight incubation of HUVECs with PTX did not
alter the magnitude of compound 48/80-evoked ATP efflux
(95.2F13.9% (N=22) of buffer-pretreated HUVECs). Fur-
thermore, PTX treatment did not significantly affect the
temporal onset (43.8F3.0 s, N=22) of G protein-initiated
release of ATP. Thus, a Gq protein is the probable initiation
site for compound 48/80-induced ATP efflux.
Addition of compound 48/80 to HUVECs also stimulated
increases in intracellular Ca2+ as depicted in Fig. 3A.
83.7F3.3% of cells responded with increased Ca2+ levels
upon addition of 15 Ag/ml compound 48/80 (N=15). The
temporal onset and maxima of Ca2+ increase were at
37.3F1.5 and 51.2F1.9 s (N=42), respectively. The
temporal onsets of both Ca2+ and ATP release were quite
similar. Thus, the ATP and Ca2+ responses were furtherFig. 4. Phospholipase C dependence of compound 48/80-induced release of ATP
inhibitor U73122 (10 AM) or its inactive analog U73343 (10 AM). Removal of extr
was performed with 10 AM U73122 (U73122/EGTA) to further investigate the rol
and Ca2+ signaling (B) are depicted for cells stimulated with 15 Ag/ml compoundinvestigated to determine whether: (1) the Ca2+ increase was
the result of ATP release, (2) the Ca2+ increase was
necessary for the release of ATP, or (3) the two were simply
two parallel results of the same stimulation. Thapsigargin,
an inhibitor of Ca2+ ATPases, was employed to deplete
intracellular Ca2+ stored within the ER, and 100 AM EGTA
in Ca2+-free buffer was used to remove the extracellular
Ca2+ source. As depicted in Fig. 3B, compound 48/80-
stimulated cells pretreated for 20 min with Tg an Ca2+-free
buffer did not release significant amounts of ATP
(5.9F2.7% of control, N=6). Also, the temporal onset of
ATP release under these conditions was significantly
delayed (initiation at 84.6F10.7 s) for HUVECs that did
exhibit ATP release. Ca2+ imaging confirmed that under
Ca2+-free conditions, compound 48/80 did not cause
significant Ca2+ increases (3.2F2.3% of cells responded,
N=9) in HUVECs as shown in Fig. 3C. This data suggestsfrom HUVECs. HUVECs were pretreated for 20 min with either the PLC
acellular Ca2+ by pretreatment in Ca2+-free buffer containing 100 AM EGTA
e of PLC on release of ATP. Representative time courses of ATP release (A)
48/80.
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strictly Ca2+-dependent.
Based on these results, the possibility that increasing
intracellular Ca2+ levels alone was sufficient for initiating
ATP efflux from HUVECs was investigated. Exposure of
cells to the Ca2+ ionophore A23187 (10 AM) in buffer
containing 4 mM CaCl2 (double that of the control imaging
buffer) failed to stimulate significant release of ATP without
the addition of compound 48/80. As shown in Fig. 3B,
A23187 caused 5.2F0.3% (N=3) of the ATP release found
with 15 Ag/ml compound 48/80, while buffer alone
produced 4.5F1.7% (N=3). Ca2+ imaging demonstrated
that intracellular Ca2+ was increased in 89.6F0.6% (N=3) of
cells, as depicted in Fig. 3C. Likewise, direct stimulation of
HUVECs with 5 AM thapsigargin increased intracellular
Ca2+ levels in 92.1F4.2% (N=3) of cells (Fig. 3C), but was
unable to induce release of ATP (4.8F0.7% (N=3) versusFig. 5. Protein kinase C dependence of compound 48/80-induced release of ATP
Go6893, both PKC inhibitors (A), or with 1 AM PMA or 1 AM indolactam V (Ind
depicted for cells stimulated with 15 Ag/ml compound 48/80.release caused by compound 48/80), as illustrated in Fig.
3B. These experiments provide evidence that ATP release
from HUVECs was dependent on increased intracellular
Ca2+ levels, but that increasing intracellular Ca2+ levels was
not sufficient to cause release.
Next, experiments were conducted to determine
whether the Ca2+-based control of G protein-initiated
ATP release in HUVECs was exerted through the well-
established phospholipase C/IP3 pathway. Prior to stim-
ulation, cells were incubated for 30 min in imaging
buffer containing either U73122 or U73343, an inhibitor
of phospholipase C and its inactive analog, respectively.
When stimulated with compound 48/80 under extracel-
lular Ca2+-free conditions, ATP release from HUVECs
was significantly inhibited in cells pretreated with
U73122 (12.7F3.4% of cells compared to those pre-
treated with U73343, N=6), as shown in Fig. 4A. Whenfrom HUVECS. HUVECs pretreated for 30 min with 5 AM BIM and 1 AM
o), both PKC activators (B). Representative time courses of ATP release are
Fig. 6. Nitric oxide dependence of compound 48/80-induced release of
ATP from HUVECS. HUVEC dishes were pretreated for 30 min with
either 100 AM l-NAME, 10 AM l-NMMA, or buffer. Representative time
courses of ATP release are depicted for cells stimulated with 15 Ag/ml
compound 48/80.
Fig. 7. Effect of glybenclamide pretreatment on compound 48/80-induced
release of ATP form HUVECs. HUVECs were treated with 100 AM
glybenclamide (Glyb) or buffer prior to stimulation with 15 Ag/ml
compound 48/80. Representative time courses of ATP release are depicted.
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U73122 still attenuated stimulated ATP release but to a
lesser degree (20.9F8.9% compared to U73343-treated
cells, N=4). Ca2+ imaging confirmed that intracellular
Ca2+ signaling was reduced in compound 48/80-stimu-
lated HUVECs pretreated with U73122 with and without
extracellular Ca2+ present. As shown in Fig. 4B,
64.6F10.6% (N=4) of cells responded with increased
Ca2+ when cells were pretreated with U73122 compared
to 81.4F4.1% (N=8) of cells pretreated with U73343.
Additionally, when Ca2+ was removed, only 25.0F10.6%
(N=12) of U73122 treated cells responded with increased
Ca2+ versus 67.7F16.0% (N=4) for U73343. The
temporal initiation of ATP release was extended slightly
in cells pretreated with U73122 (49.5F9.1 and
49.4F12.3 s under Ca2+-free conditions and Ca2+-present
conditions, respectively), for those cells in which release
was detected (three of seven for U73122 under Ca2+-free
conditions and five of seven for U73122 under Ca2+-
present conditions). Moreover, U73343 did not appear to
affect ATP or Ca2+ signaling. The temporal response of
compound 48/80-stimulated cells pretreated with U73343
with and without Ca2+ present was not significantly
different than those obtained for either buffer or EGTA
treatment (data not shown). Together with the earlier
experiments, these results suggest that G protein-activated
release of ATP proceeds via activation of phospholipase
C and subsequent increases in intracellular Ca2+.
The protein kinase C dependence of G protein-initiated
ATP release was also examined. Phospholipase C, which
produces IP3, additionally generates diacylglycerol (DAG).
When activated by DAG, protein kinase C modulates Ca2+
signaling in HUVECs [24] and thus could be involved in
ATP release. As illustrated in Fig. 5A, pretreatment with
neither BIM nor Go6893, both inhibitors of PKC, altered
the magnitude of compound 48/80-stimulated release of
ATP (102.8% F4.9, N=7 and 95.1% F8.9, N=6 of controls,
respectively). Likewise, pretreatment with BIM or Go6893
did not significantly affect the temporal onset of ATPrelease. Hence, activation of PKC did not appear to be
necessary for compound 48/80-induced release of ATP.
Next, the effect of PKC activation on ATP efflux was
studied using the PKC activators PMA and indolactam V.
Fig. 5B shows the ATP release for compound 48/80-
stimulated HUVECs pretreated with PMA and indolactam
V. As depicted, treatment with the PKC activators reduced
the magnitude of stimulated ATP release from HUVECs
(14.2F3.4, N=7 and 56.8F9.9%, N=7 of control, respec-
tively). The temporal initiation of ATP release was delayed
in compound 48/80-stimulated HUVECs pretreated with
PKC activators (59.9F8.6 s, N=10 and 49.7F3.1 s, N=7 for
PMA and indolactam V, respectively) versus buffer only
(41.2F1.8 s).
We then examined whether the production of nitric oxide
was involved in G protein-initiated release of ATP in
HUVECs. As mentioned earlier, increases in intracellular
Ca2+ activate nitric oxide synthase (NOS). The results of
experiments conducted with the NOS inhibitors l-NAME
and l-NMMA are depicted in Fig. 6. The magnitude of
compound 48/80-stimulated release of ATP was not
significantly altered in either l-NAME- or l-NMMA-
pretreated cells (96.0F6.7%, N=8 and 95.7F8.3%, N=7
of untreated cells, respectively). Additionally, the temporal
onset of ATP release for inhibitor-treated cells was not
significantly different from that of control cells. Thus, it
appears that nitric oxide production is not necessary for G
protein-initiated release of ATP.
Finally, we wanted to determine if compound 48/80-
induced release of ATP in HUVECs occurred via a CFTR-
transmembrane ion channel. Glybenclamide blocks CFTR
channels and is commonly employed to identify CFTR-
coupled release. In HUVECs treated with 100 AM glyben-
clamide, compound 48/80-induced release of ATP was not
significantly modified. As shown in Fig. 7, the magnitude of
release was 96.3F10.3% (N=6) of control dishes and its
onset occurred at 39.3F2.9 s. These results generally
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was not occurring through a CFTR channel.4. Discussion
The above observations provide insights into the path-
way through which HUVECs release ATP when stimulated
with the mast cell degranulator compound 48/80. Com-
pound 48/80 likely initiates the release pathway by
activating a Gq protein which has been previously identified
in HUVECs [25]. In general, Gq proteins are not pertussis
toxin-sensitive [26], which supports this hypothesis. How-
ever, both compound 48/80 and mastoparan must permeate
the cell membrane in order to activate a G protein. This
permeation could make the membrane permeable to ATP as
well. However, the release of ATP in this case was
eliminated with the removal of cell Ca2+ sources. The
possibility remains that the permeability of the membrane to
compound 48/80, and therefore ATP, is decreased in the
absence of Ca2+. However, the inhibition of PLC also
attenuated ATP release without the elimination of the
cellular Ca2+ sources. These results suggest that the release
mechanism was physiologically initiated but do not
completely negate the involvement of an increase in
membrane permeability. The next step in the release
pathway appeared to be the activation of PLC by the Gq
protein. PLC then produced IP3 which caused release of
Ca2+ from the ER, which was followed by initiation of
capacitive Ca2+ entry from the extracellular matrix [27].
Following this increase in intracellular Ca2+, ATP was
released from the cell into the extracellular medium. Up-
regulation of PKC significantly attenuated ATP release.
PKC activation, by treatment of the cells with PKC
activators for ~20–30 min, has been reported to inhibit
PLC in many cell types, including endothelial cells [28,29].
The rate and magnitude of release under conditions of PKC
activation in our experiments were similar to those in
U73122-treated HUVECs. This suggested that protein
kinase C possibly down-regulated phospholipase C in our
system and could act in feedback inhibition of ATP release
upon extended stimulation of the release mechanism.
The maximal release induced by addition of compound
48/80 was 4 AM ATP. From calcein imaging data, the
observation area of the microscope contained, on average,
134 endothelial cells. Taking an average volume of 1 Al per
106 cells, the cells in the observation area contain
2.68107 Amol of ATP. The imaging volume is
~2.71106 ml, taking into account the depth of field of
our microscope objective. Utilizing this volume, the 4 AM
ATP detected represents 1.08108 Amol of ATP. Thus, the
maximal release of ATP in these experiments represents
release of ~4% of the total ATP. This is likely a slight
overestimate of the actual release as at least part of the depth
of field of the microscope is below the cells, and thus yields
no signal. This magnitude of release is significantly higherthan that reported in other ATP release studies [Ref.
[17,36]]. As demonstrated by Dubyak and colleagues, the
release of up to 100 nM ATP in astrocytes can be effectively
enzymatically degraded by ecto-ATPases on the outer
plasma membranes. This likely limits the actions of released
ATP to cells immediately neighboring the releasing cells.
Additionally, the ecto-ATPases could also act in eliminating
the effect of low level ATP release, such as from basal
release across the cell membrane. For Gq protein-induced
ATP release from endothelial cells, the level of ATP release
can likely overcome the action of the ecto-ATPases and
have more profound effects in cellular systems.
As observed above, increasing Ca2+ alone is not
sufficient to induce release of ATP. Many possibilities exist
as to what other metabolic pathways/enzymes are necessary
for inducing release of ATP from HUVECs upon G protein
stimulation. For instance, photoliberation of IP3 can induce
release of ATP in astrocytes [37], and could be adequate in
HUVECs, as well. Alternatively, the simultaneous activa-
tion of another cellular pathway by compound 48/80 may be
necessary for release to occur. Activation of an alternative
pathway by the G protein (either the a- or hg-subunit) could
feasibly be involved. Platelet-activating factor stimulation of
Gaq has been shown to stimulate numerous second
messenger pathways in HUVECs, including both PLC
activation and increased cAMP levels [38]. In mast cells,
G protein hg-subunits are implicated in controlling exocy-
tosis while they are not sufficient by themselves to trigger
exocytosis. Instead, Gomberts et al. suggest that activation
of Rho-related GTPases is likely necessary for induction of
exocytosis [39]. This mechanism is further postulated in the
action of both compound 48/80 and mastoparan activation
of mast cells.
A number of recent studies have been published which
are especially interesting in light of the results obtained in
this work. Stout et al. [21] reported ATP release through
connexin hemichannels in mechanically stimulated astro-
cytes. They noted that cells loaded with calcein blue dye
(MW=400 Da) released the dye upon mechanical stimula-
tion. However, neither Oregon Green (MW=1100 Da) nor
LDH (MW=134 kDa) was released under these same
conditions. Moreover, the connexin channel inhibitor
flufenamic acid attenuated the release of both calcein blue
and ATP. Arcuino et al. [23] undertook a similar study. They
noted that ATP was released in astrocytes upon lowering
extracellular Ca2+ levels. Fluorescence imaging revealed
propidium (MW=563 Da) and dicarboxy-dichlorofluores-
cein (MW=445 Da) uptake also occurred upon stimulation.
However, fluorescein–dextran conjugates (MW=1.5–2000
kDa) were unable to enter the astrocytes under identical
conditions. Furthermore, connexin-deficient C6 glioma did
not release ATP when stimulated. Like Stout and coworkers,
Arcuino and colleagues hypothesized that connexin hemi-
channels may be the channel through which ATP efflux
occurs. Finally, they also reported release of ATP from
HUVECs and epithelial cells stimulated identically to the
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astrocytes has not been identified. However, ATP release in
both of these reports would correlate well with the pathway
investigated here. We noted that HUVECs stimulated with
compound 48/80 were still able to load and maintain calcein
after compound 48/80 washout. However, we also observed
that calcein preloaded into HUVECs was released upon
stimulation with compound 48/80 while LDH was not.
Moreover, compound 48/80 was able to stimulate release of
ATP from astrocytes, and like in HUVECs, this release of
ATP was found to be Ca2+-dependent (Gruenhagen, J.A.
and Yeung, E.S., unpublished data).
Exocytosis of ATP is another possible mechanism for
release. Both compound 48/80 and mastoparan are com-
monly used to study secretion of histamine from mast cells
through activation of Gi proteins. As is typically the case in
exocytosis, we observed a strict dependence on Ca2+ in our
experiments. However, unless calcein was confined to
exocytotic vesicles, the observed calcein leak experiments
are difficult to explain. Calcein fluorescence, in fact, was
found to be very uniform across the cell, suggesting this was
not the case. Furthermore, the involvement of a Gi protein in
the release mechanism was widely negated as treatment with
pertussis toxin was without effect. Nonetheless, it is still
possible that exocytosis of ATP and release of ATP from the
cytoplasm occur simultaneously upon introduction of
compound 48/80. We found no data to suggest the release
of ATP occurred through the ATP binding cassette (ABC)
protein, CFTR. ATP release stimulated by compound 48/80
was not inhibited by glybenclamide, which is in contrast to
the majority of proposed CFTR-permeable ATP release
mechanisms [17]. Furthermore, these results also suggest
against the involvement of a sulfonylurea receptor in ATP
release. Several other mechanisms for release of ATP have
been proposed. These include release through large-con-
ductance and volume-regulated anion channels [30,31].
Unfortunately, the luciferase imaging reaction was inhibited
in the presence of DIDS. Thus, we could not negate the
involvement of these channels. The involvement of other
ABC proteins possibly involved in release, including P-
glycoprotein, was not examined in this report and deserves
future scrutiny. Identification of the true release mechanism
in HUVECs will necessitate eliminating all of the other
proposed ATP release schemes through the use of appro-
priate activators and inhibitors and an in-depth investigation
of each mechanism.
The physiological role of ATP release in endothelial cells
in vivo has not been thoroughly elucidated but many
possibilities exist. As discussed earlier, released ATP causes
the activation of several pathways in numerous cell types. In
addition, endothelial cells interact with many different cell
types in the human body. These include smooth muscle cells
around the blood vessels, glial cells in the brain, platelets
and neutrophils in the blood, and other endothelial cells
[32]. One possible physiological effect of release of ATP
from endothelial cells would be in regulating vasodilation/vasoconstriction of blood vessels. Stimulants either carried
in the blood or released by cells carried in the blood could
stimulate Gq protein-coupled receptors on the endothelial
cells. The stimulated endothelial cells would then release
ATP onto neighboring smooth muscle cells and onto other
unstimulated endothelial cells. This ATP would modulate
vasoconstriction via activation of P2X receptor ion chan-
nels. Additionally, ATP has been shown to induce the
synthesis of nitric oxide, a major modulator of vascular
smooth muscle tone, in endothelial cells [9]. Therefore,
release of ATP from endothelial cells might regulate smooth
muscle function through a balance between activation of
ionotropic purinergic receptors on the smooth muscle cells
and stimulation of nitric oxide production by neighboring
endothelial cells [10]. Glial cell/endothelial cell interactions
are responsible for communication across the blood brain
barrier [32]. Activation of Gq protein-coupled receptors on
endothelial cells by either the glial cells or compounds
carried in the blood could induce ATP efflux. ATP would
then act on neighboring endothelial cell purinergic receptors
regulating the microvascular permeability via control of
intracellular Ca2+ signaling and cAMP levels [33]. Perhaps
more importantly, released ATP would activate Ca2+ signal-
ing in glial cells, which has been implicated in the
modulation of neuronal synaptic transmission [5,6]. ATP
release from endothelial cells also appears to be exceedingly
important in inflammation and wound healing. For instance,
ATP released by endothelial cells can cause degranulation in
mast cells, releasing histamine and additional ATP. This
ATP would then stimulate degranulation of additional
neighboring mast cells. ATP released by endothelial cells
also initiates Ca2+ signaling in platelets and neutrophils,
inducing their aggregation at wound sites[34]. The balance
between release of ATP and NO, which inhibits platelet
aggregation, could regulate inflammatory response in the
vascular system. Whether Gq protein-induced release of
ATP participates in any of these or other physiological
systems remains to be fully clarified. Additionally, further
research is necessary to identify the actual physiological
stimulants that induce Gq protein-initiated ATP release in
HUVECs and possibly in other cell types.
In summary, the activation of G proteins in HUVECs by
compound 48/80 was investigated. It was discovered that
ATP is released upon stimulation of the cells. This release,
which was seemingly initiated via a Gq protein, was
modulated by PLC and subsequent Ca2+ signaling. It did
not appear to occur through the known CFTR ion channel or
exocytosis mechanisms but instead through an as of yet
unidentified cytoplasmic channel.Acknowledgement
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